skip to main content

EMERGING
SOLUTIONS
RECALIBRATE
CARE FOR
SUSTAINABILITY

With medical and pharmacy cost trends on the rise, we’re committed to helping you meet the challenge of managing cost without compromising care. We designed our emerging pharmacy solutions to remove financial barriers while creating more meaningful member engagement and support — essential steps to transform care delivery and protect the sustainability of your benefits.

graph

11%

INCREASE

Industry-wide, the 2026
prescription cost trend is
projected to exceed the
expected 8.5% medical trend
by 2.5 percentage points.1

pill

50%

ADHERENCE

Despite rising drug and
total health care costs,
nearly 50% of people
aren’t taking their drugs
as prescribed.2

money

>50%

of PHARMACY
COSTS

Less than 5% of the
population needs specialty
medications, yet these drugs
make up at least half of
pharmacy costs.3

Built to elevate care and drive clinical efficiency, these emerging solutions will empower members to get the right care in ways that are safe and effective.

Click below to learn how our newest pharmacy concepts aim to improve the health of your employees, your benefits and your business.

Accessibility, Affordability and Member Empowerment Start Here

Health care is personal, sometimes complex, and always evolving. Members and employers
need trusted resources and guidance. We’re here to navigate the changes with you, finding new
ways to keep health care safe, effective and deeply human.

Download PDF Adobe Acrobat Icon
  1. PricewaterhouseCoopers (PwC), Medical Trend: Behind the Numbers 2026
  2. Value in Health, Volume 28, Issue 5, May 2025; “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report” Bijan J. Borah Lisa J. Pieretti Alan J. Balch Rajvi J. Wani Christopher J. Daly Dalia Dawoud David Hutchins Mickaël Hiligsmann Andrew M. Peterson Tamas Agh
  3. CarelonRx. 2025. “Specialty Drug Growth is Here to Stay.” February 25, 2025. https://www.carelonrx.com/perspectives/specialty-drug-growth leaving site icon
  4. Buttorff C, Ruder T, Bauman M. Multiple Chronic Conditions in the United States. Rand Corp.; 2017
  5. National health expenditure data: historical. Center for Medicare & Medicaid Services. Updated December 13, 2023. Accessed February 6, 2024. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/historical leaving site icon
  6. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307
  7. Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023. doi: 10.2337/dci23-0085
  8. Wesam W Ismail, MSc, Matthew J Witry, PharmD, PhD, and Julie M Urmie, PhD; Journal of Managed Care & Specialty Pharmacy Volume 29, Number 5. https://doi.org/10.18553/jmcp.2023.29.5.449 leaving site icon (specialty medications referenced as defined by the study)
  9. Business Group on Health. 2025 Employer Health Care Strategy Survey. August 2024. Available at: https://www.businessgrouphealth.org/resources/2025-Employer-Health-Care-Strategy-Survey-Intro leaving site icon
  10. Prime Therapeutics. (2025). Medical Pharmacy Trend Report. https://issuu.com/primetherapeutics/docs/2025_medical_pharmacy_trend_report?fr=sODQ4ZTgzNDUwNjE leaving site icon

KeepWell is a trademark of Prime Therapeutics, LLC. KeepWell is a product owned by Prime Therapeutics LLC which is a separate company contracted by Blue Cross and Blue Shield of IL, MT, NM, OK, and TX National Accounts to provide pharmacy solutions. National Accounts, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

KeepWell and Advocate+ Pharmacy Match are emerging solutions available in 2026. Advanced Rx Care and Medical Drug Benefit Solutions are developing products. Product and benefit descriptions may be subject to change as they are prepared for market-readiness.

Work with your Sales and Account Management team to understand group-specific anticipated outcomes. Anticipated outcomes are not a guarantee of actual performance. Actual performance is dependent on each group’s specific benefit design and utilization.